Now, there is a ready-to-use combination vaccine that provides the gold standard in protection for both circovirus and Mycoplasma hyopneumoniae.

Circumvent PCV M from Intervet/Schering-Plough Animal Health combines the proven performance of Circumvent PCV and MycoSilencer Once in a convenient combination vaccine.

The two-dose vaccine controls clinical signs of circovirus and prevents the viremia that leads to chronic circovirus infection. In licensing studies, significantly fewer pigs from the Circumvent PCV M-vaccinated group developed viremia than pigs from the placebo control group. Preventing viremia reduces the risk of pigs becoming chronically infected, which can lead to late disease breaks as pigs approach market age.

Licensing studies also showed that pigs vaccinated with Circumvent PCV M had significantly fewer lung lesions typical of Mycoplasma than did pigs in the placebo control group.

Effective, long-lasting, two-dose Mycoplasma protection, combined with the control of circovirus viremia, allows for maximum performance and less variation in finishing. “If left untreated, circovirus and Mycoplasma are two of the more costly diseases to the swine industry,” says Karen Lehe, DVM, Intervet/Schering-Plough Animal Health technical service manager. “Circumvent PCV M provides protection that pork producers have come to expect from Circumvent PCV and MycoSilencer Once, all in a convenient combination vaccine.”

The combination vaccine should be administered with a 2-mL dose intramuscularly at 3 weeks of age and another 2-mL dose at 6 weeks. It provides veterinarians and producers a new health-management tool for circovirus and Mycoplasma, combining efficacy, convenience and peace of mind. The combination product requires no mixing, so there is no risk of contamination or additional labor associated with mixing and no requirement to use within four hours.

“Circumvent PCV M boosts pork producers’ bottom line by reducing the risk of late breaks and improving performance and uniformity in finishing,” Lehe says. For more information, visit or